Targeting New Strategies in Narcolepsy and Idiopathic Hypersomnia: Novel Approaches to Diagnosis and Treatment

 A continuing medical education and nursing continuing professional
development activity provided by NAMCP and AAMCN.

This activity is an archive from the live session from the 2023 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2024 to March 1, 2025
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educationals grants from
Avadel CNS Pharmaceuticals, LLC and Jazz Pharmaceuticals

Description:
Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. It challenges work life, social life, and home life. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or obstructive sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases, it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Even when factors such as treatment adherence, medications, comorbid illness, and inadequate sleep duration are controlled, up to 33% of all Americans still experience some typical of sleep-depravity. For most people, mild sleepiness is apparent only during boring, sedentary situations, however patients with narcolepsy, severe hypersomnia, can lead to involuntary somnolence during regular activities that could put the patient and others in a harmful situation, such as driving, eating, or talking.
Idiopathic hypersomnia (IH) is a sleep disorder in which a person feels excessive tiredness, even after a full and uninterrupted night of sleep. People with this condition may sleep longer than normal, sometimes 11 or more hours a night, yet still feel tired during the day. With the potential danger surrounding narcoleptic patients, it is important for clinicians to understand and identify major sleep disorders and the best methods to diagnose and treat them. Greater awareness of sleep disorders and their symptoms can help accurately and efficiently diagnosis the disease. As research continues to grow, better treatments for narcolepsy are becoming available. Sleep studies are an essential part of the evaluation and diagnosis of patients with narcolepsy. Symptoms can include EDS, sleep paralysis, hallucinations, but cataplexy is the most specific symptom and occurs in almost no other diseases. The combination of an overnight polysomnogram (PSG) followed by a multiple sleep latency test (MSLT) can provide the proper evidence of narcolepsy while excluding other sleep disorders.

Upon completion of this activity, participants will be able to:

  • Examine AASM guidelines and recent evidence to generate personalized treatment plans for narcolepsy and idiopathic hypersomnia (IH)

  • Assess clinical characteristics and diagnostic considerations of narcolepsy and IH to improve diagnosis

  • Differentiate the clinical and functional impact of NT1 versus NT2 considerations of narcolepsy and IH

  • Evaluate recent clinical trial data on the efficacy, safety, and mechanisms of action of new and emerging therapies in the management of narcolepsy and IH

  • Understand the barriers and challenges associated with treating IH to create optimal solutions for patients

  • Analyze the different interventions for developing treatment pathways that address the unique needs of patients with narcolepsy and IH to improve patient outcomes
     

Faculty: Anne Marie Morse, DO, FAASM
Director, Pediatric Sleep Medicine
Clinical Associate Professor
Geisinger Commonwealth School of Medicine
Geisinger Medical Center

As accredited providers, NAMCP and AAMCN must ensure balance, independence, objectivity, and scientific rigor in all of their activities. All faculty participating in this activity are required to disclose to NAMCP/AAMCN any financial relationships with ineligible companies. NAMCP/AAMCN in turn discloses all relevant financial conflicts to the learners. NAMCP/AAMCN disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. See below for conflicts of interest.

Disclosure:

Disclosures (Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Morse has served as a consultant for Alkermes, Avadel, Harmony Biosciences, Jazz, and Takeda. She has served on an advisory board for Neura. She has served as a speaker for Avadel and Jazz. All relevant conflicts of interest have been mitigated.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Avadel CNS Pharmaceuticals, LLC and Jazz Pharmaceuticals


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue